

Medscape

A Free, Internet-Based Activity

Brain Glucose Hypometabolism, Ketosis, and Alzheimer Disease: From Controversy to Consensus CME

Richard S. Isaacson, MD, Associate Professor of Neurology; Director, Alzheimer's Prevention and Treatment Program, Weill Cornell Medical College, New York, New York

Stephen C. Cunnane, PhD, Professor of Medicine and Physiology, University of Sherbrooke; Former Director, Research Center on Aging, Sherbrook University Geriatric Institute, Sherbrooke, Quebec, Canada

Russell H. Swerdlow, MD, Professor of Neurology; Director, University of Kansas Alzheimer's Disease Center, Kansas University Medical Center Neurodegenerative Disorders Program, Kansas City, Kansas

Visit www.medscape.org/spotlight/brainketosis

Supported by an independent educational grant from:



A Free, Internet-Based Activity

Brain Glucose Hypometabolism, Ketosis, and Alzheimer Disease: From Controversy to Consensus CME

Target Audience

This activity is intended for neurologists, primary care physicians, and other healthcare practitioners involved in the diagnosis and treatment of Alzheimer disease.

Learning Objectives

- 1. Identify and evaluate the results of clinical research on brain glucose hypometabolism as a pathologic characteristic of Alzheimer disease
- 2. Describe the rationale for treatment to address brain glucose hypometabolism
- 3. Compare and contrast strategies to induce ketosis to address brain glucose hypometabolism

Accreditation For Physicians



Medscape, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.50 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To access this free CME activity, visit www.medscape.org/spotlight/brainketosis First-time visitors will be asked to register for free.